Medical researchers at Johns Hopkins University in the United States have found more evidence that a tuberculosis vaccine reduces the risk of dementia setting in.
They also discovered indications that “trained immunity” in cells plays a part in stalling the onset of dementia.
In tests on mice, the team found that those administered the household-name jab Bacillus Calmette-Guérin (BCG) “were less likely to show hallmark signs of the disease”, such as memory loss, compared to those who were left unvaccinated.
“BCG is a safe, readily-available therapy that merits consideration as a preventive agent against dementia,” the researchers concluded in their paper, which was published in the journal Science Advances.
“We’re hard at work trying to understand the detailed mechanism for how it works, but this research points to early clues that aspects of trained immunity are likely driving this response,” says study corresponding author and Johns Hopkins Center for Tuberculosis Research co-director Dr William Bishai.
Trained immunity refers to how mammals’ “first responder” immune system cells can sometimes take on “an expanded role” following stimulation – in this case, partly prompted by the BCG injection, which is sometimes used to treat bladder cancer.
The jab “seems to be reducing the degree of hyperinflammation in the brain,” said Dr Bishai, who added that “it may be doing it through a trained immune cell mechanism”.
Earlier this year (2026), Massachusetts General Hospital and Harvard University researchers revealed a “potential biological explanation” for the BCG-dementia link following years of “previously observed associations”.
The jab “changed how immune cells behaved, including in the fluid surrounding the brain and spinal cord, and altered markers linked to Alzheimer’s disease,” the Boston-based team said. – dpa















